Published in AIDS Res Hum Retroviruses on July 08, 2014
Oral administration of the nucleoside EFdA (4'-ethynyl-2-fluoro-2'-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. Antimicrob Agents Chemother (2015) 0.88
Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering. J Clin Microbiol (2015) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med (2006) 8.35
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (2006) 3.70
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis (2008) 3.15
The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis (2004) 2.76
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science (2010) 2.19
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis (2004) 2.02
Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev (2012) 1.95
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis (2008) 1.91
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr (2012) 1.84
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS (2007) 1.81
Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS (2002) 1.78
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ (2012) 1.71
Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother (2007) 1.70
The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. AIDS (2009) 1.65
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS (2007) 1.60
Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS (2004) 1.53
Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis (2009) 1.50
Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med J (2011) 1.48
Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother (2008) 1.47
Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS (2007) 1.46
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses (2002) 1.45
Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005. Enferm Infecc Microbiol Clin (2011) 1.43
Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir Ther (2009) 1.42
Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities. HIV Clin Trials (2007) 1.41
Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis (2005) 1.39
Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials (2008) 1.32
Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. PLoS One (2010) 1.29
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS (2013) 1.29
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS (2003) 1.24
Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS (2010) 1.20
A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr (2006) 1.19
Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS (2003) 1.17
The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes. J Acquir Immune Defic Syndr (2008) 1.16
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother (2007) 1.16
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS (2010) 1.15
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS (2008) 1.11
Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Ann Pharmacother (2005) 1.11
Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One (2011) 1.09
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother (2010) 1.09
Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother (2007) 1.06
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr (2009) 1.05
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS (2009) 1.04
Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinic. AIDS (2006) 1.02
Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med (2004) 1.01
Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. AIDS (2004) 1.00
Prevalence of sexually acquired antiretroviral drug resistance in a community sample of HIV-positive men who have sex with men in New York City. AIDS Patient Care STDS (2011) 1.00
Molecular phylogenetics of transmitted drug resistance in newly diagnosed HIV Type 1 individuals in Denmark: a nation-wide study. AIDS Res Hum Retroviruses (2011) 0.99
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother (2009) 0.99
Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. AIDS Res Hum Retroviruses (2007) 0.98
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria. AIDS Res Hum Retroviruses (2008) 0.98
Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. Eur J Med Res (2002) 0.97
Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe. HIV Clin Trials (2009) 0.96
Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother (2009) 0.95
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J Infect Dis (2003) 0.95
Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. AIDS Res Hum Retroviruses (2007) 0.95
Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis (2013) 0.94
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther (2003) 0.93
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One (2011) 0.93
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther (2008) 0.93
Molecular and epidemiological characterization of HIV-1 infection networks involving transmitted drug resistance mutations in Northern Greece. J Antimicrob Chemother (2011) 0.93
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother (2011) 0.93
Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS (2010) 0.92
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. J Antimicrob Chemother (2013) 0.92
Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther (2006) 0.92
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs. BMC Infect Dis (2009) 0.92
Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS (2002) 0.91
Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. Clin Infect Dis (2004) 0.91
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother (2009) 0.91
Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother (2004) 0.90
Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis (2005) 0.90
Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004. Virus Res (2006) 0.90
HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res Hum Retroviruses (2004) 0.90
Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir Ther (2009) 0.90
Transmitted HIV-1 drug resistance among young men of color who have sex with men: a multicenter cohort analysis. J Adolesc Health (2010) 0.89
Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve, HIV-infected individuals in New York State. AIDS Patient Care STDS (2007) 0.89
Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. J Clin Virol (2012) 0.89
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr (2008) 0.89
Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. PLoS One (2011) 0.89
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS (2002) 0.89
Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains. Int J Infect Dis (2006) 0.88
Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007. Transfusion (2010) 0.88
HIV-1 subtypes in Luxembourg, 1983-2000. AIDS (2002) 0.88
Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches. Curr Opin Investig Drugs (2006) 0.87
Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. Antivir Ther (2009) 0.87
Genetic analysis of HIV type 1 strains from newly infected untreated patients in cyprus: high genetic diversity and low prevalence of drug resistance. AIDS Res Hum Retroviruses (2009) 0.87
The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients. PLoS One (2013) 0.87
Emerging transmitted drug resistance in treatment-naïve human immunodeficiency virus-1 CRF06_cpx-infected patients in Estonia. Scand J Infect Dis (2010) 0.87
Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. J Med Virol (2005) 0.87
Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. AIDS (2010) 0.87
Mindfulness-based psychotherapies: a review of conceptual foundations, empirical evidence and practical considerations. Aust N Z J Psychiatry (2006) 4.31
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med (2008) 4.12
Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension (2006) 4.07
Frequency, cost, and risk factors of readmissions among severe sepsis survivors. Crit Care Med (2015) 2.50
Polypharmacy: misleading, but manageable. Clin Interv Aging (2008) 2.31
Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant (2003) 2.22
Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol (2013) 2.06
Silent strokes in patients with heart failure. J Card Fail (2005) 1.78
Muscle architecture predicts maximum strength and is related to activity levels in cerebral palsy. Phys Ther (2010) 1.73
Comparison of resting energy expenditure prediction methods with measured resting energy expenditure in obese, hospitalized adults. JPEN J Parenter Enteral Nutr (2009) 1.56
Improved detection of Mycobacterium tuberculosis in Peruvian children by use of a heminested IS6110 polymerase chain reaction assay. Clin Infect Dis (2002) 1.56
Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest (2003) 1.54
Experience with an adult alcohol withdrawal syndrome practice guideline in internal medicine patients. Pharmacotherapy (2005) 1.45
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr (2005) 1.43
Comparison of self-report versus agency records of service utilization in a community sample of individuals with alcohol use disorders. Drug Alcohol Depend (2004) 1.30
Dietary fiber for the treatment of type 2 diabetes mellitus: a meta-analysis. J Am Board Fam Med (2012) 1.23
Hospital care for patients experiencing weekend vs weekday stroke: a comparison of quality and aggressiveness of care. Arch Neurol (2010) 1.22
In-hospital cost of total hip arthroplasty in Canada and the United States. J Bone Joint Surg Am (2004) 1.19
Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother (2004) 1.12
Timing of elective repeat cesarean delivery at term and neonatal outcomes: a cost analysis. Am J Obstet Gynecol (2010) 1.10
Cost-effectiveness of maternal treatment to prevent perinatal hepatitis B virus transmission. Obstet Gynecol (2011) 1.09
Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology (Oxford) (2009) 1.08
Do diabetes group visits lead to lower medical care charges? Am J Manag Care (2008) 1.07
Impact of a hospital-acquired/ventilator-associated/healthcare-associated pneumonia practice guideline on outcomes in surgical trauma patients. J Trauma (2010) 1.03
Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res (2012) 1.01
The one-year attributable cost of poststroke aphasia. Stroke (2012) 0.98
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials (2010) 0.98
Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectr (2004) 0.97
Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res (2004) 0.97
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. J Acquir Immune Defic Syndr (2013) 0.96
Outcomes and cost of coronary artery bypass graft surgery in the United States and Canada. Arch Intern Med (2005) 0.96
Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients. Antimicrob Agents Chemother (2011) 0.95
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob Agents Chemother (2007) 0.94
Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther (2004) 0.94
Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin (2010) 0.92
Reducing emergency department visits among high-using patients. J Fam Pract (2003) 0.92
Barriers facing patients referred for kidney transplant cause loss to follow-up. Kidney Int (2012) 0.91
Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract (2013) 0.91
Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma (2008) 0.91
Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig (2009) 0.90
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study). J Acquir Immune Defic Syndr (2006) 0.90
Hospital readmissions following abdominal aortic aneurysm repair. Ann Vasc Surg (2005) 0.89
Potential cost savings of decreased emergency department visits through increased continuity in a pediatric medical home. Ambul Pediatr (2004) 0.89
Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine (2003) 0.88
Responsiveness of the MOS-HIV and EQ-5D in HIV-infected adults receiving antiretroviral therapies. Health Qual Life Outcomes (2013) 0.88
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients. Pharmacoeconomics (2011) 0.87
Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res (2013) 0.87
The prevalence of transmitted resistance to first-generation non-nucleoside reverse transcriptase inhibitors and its potential economic impact in HIV-infected patients. PLoS One (2013) 0.87
Perioperative myocardial ischemic injury in high-risk vascular surgery patients: incidence and clinical significance in a prospective clinical trial. J Vasc Surg (2006) 0.86
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study. J Acquir Immune Defic Syndr (2013) 0.86
The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios. Pharmacoeconomics (2004) 0.85
Design of the economic evaluation for the Interventional Management of Stroke (III) trial. Int J Stroke (2008) 0.84
Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials. BMC Neurol (2011) 0.84
Patient reported outcome instruments used in clinical trials of HIV-infected adults on NNRTI-based therapy: a 10-year review. Health Qual Life Outcomes (2013) 0.84
Breast cancer screening, incidence, and mortality in West Virginia. W V Med J (2009) 0.84
Prevalence, healthcare utilization, and costs of breast cancer in a state Medicaid fee-for-service program. J Womens Health (Larchmt) (2011) 0.84
Impact of age on hospital course and cost of coronary artery bypass grafting. Am J Cardiol (2004) 0.83
Impact of an alcohol withdrawal syndrome practice guideline on surgical patient outcomes. Pharmacotherapy (2003) 0.83
On the road to well-being: the development of a communication framework for sexual health. Public Health Rep (2013) 0.83
In-hospital cost of abdominal aortic aneurysm repair in Canada and the United States. Arch Intern Med (2003) 0.83
Syringyl lignin is unaltered by severe sinapyl alcohol dehydrogenase suppression in tobacco. Plant Cell (2011) 0.82
Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. J Antimicrob Chemother (2009) 0.82
Influence of real-world characteristics on outcomes for patients with methicillin-resistant Staphylococcal skin and soft tissue infections: a multi-country medical chart review in Europe. BMC Infect Dis (2014) 0.81
Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug Alcohol Depend (2012) 0.81
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. Cost Eff Resour Alloc (2007) 0.81
Charges for hospital admissions attributable to health disparities for African-American patients, 1998-2002. J Natl Med Assoc (2006) 0.81
Making progress in the management of postoperative pain: a review of the cyclooxygenase 2-specific inhibitors. Pharmacotherapy (2004) 0.80
A Severe Sepsis Mortality Prediction Model and Score for Use With Administrative Data. Crit Care Med (2016) 0.80
Health care provider perception of chronic kidney disease: knowledge and behavior among African American patients. BMC Nephrol (2014) 0.80
Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol (2002) 0.80
The synaptonemal complex protein ZYP1 is required for imposition of meiotic crossovers in barley. Plant Cell (2014) 0.79
Coronary artery bypass graft surgery: do women cost more? Can J Cardiol (2005) 0.79
Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naïve HIV patients screened for Study A4001078. Antiviral Res (2012) 0.79
A cost analysis of nonelective coronary artery bypass graft surgery. J Card Surg (2006) 0.79
Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. J Pain Res (2013) 0.79
Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence. J Am Pharm Assoc (2003) (2014) 0.78
Assessment of CaMV-mediated gene silencing and integration of CaMV into GM plants with a 35S RNA promoter. Environ Biosafety Res (2007) 0.78
The cost of Medicaid savings: the potential detrimental public health impact of neonatal circumcision defunding. Infect Dis Obstet Gynecol (2012) 0.78
Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. Curr Med Res Opin (2005) 0.78
Review of the impact of NNRTI-based HIV treatment regimens on patient-reported disease burden. AIDS Care (2013) 0.78
Effects of organizational context on Lean implementation in five hospital systems. Health Care Manage Rev (2016) 0.77
Discharge disposition after bariatric surgery. Obes Surg (2014) 0.77
New hospital telemedicine services: potential market for a nighttime telehospitalist service. Telemed J E Health (2014) 0.77
Cost effectiveness of an inpatient influenza immunization assessment and delivery program for children with asthma. J Hosp Med (2008) 0.77
Identification and characterization of barley RNA-directed RNA polymerases. Biochim Biophys Acta (2009) 0.77
Correlation of LUMO localization with the alpha-amylase inhibition constant in a Tendamistat-based series of linear and cyclic peptides. Bioorg Med Chem (2005) 0.77
A cost-effectiveness analysis of inhaled corticosteroid delivery for children with asthma in the emergency department. J Pediatr (2012) 0.76
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen. Antivir Ther (2006) 0.76
HIV economic burden of illness in the Veterans Health Administration population. AIDS Care (2014) 0.76
Evaluating health services research capacity building programs: implications for health services and human resource development. Eval Program Plann (2012) 0.76
Ectopic 5' splice sites inhibit gene expression by engaging RNA surveillance and silencing pathways in plants. Plant Physiol (2009) 0.76